Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.

Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote

AstraZeneca

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

Johnson & Johnson

Novavax

Pfizer

Vir Biotechnology

Could biotech stocks be top buys as the world battles a new Covid-19 variant?

5 Biotech Stocks For Your December 2021 Watchlist

It's likely that Merck's COVID-19 pill will be authorized in the U.S. this month even though Wall Street's interest has cooled and physicians have raised questions about the drug's efficacy and safety profile, particularly among people who are pregnant.

After high hopes for Merck's COVID-19 pill, Wall Street now expects a ‘tepid' authorization

The FDA has accepted for priority review Merck & Co Inc's (NYSE: MRK) supplemental application seeking approval for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the prevention of invasive pneumococcal disease in children six weeks through 17 years of age.  The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of April 1, 2022.

Merck's Pneumococcal 15-valent Conjugate Vaccine Under Priority FDA Review For Use In Kids

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's VAXNEUVANCE™ for Use in Infants and Children

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

The FDA's Antimicrobial Drugs Advisory Committee voted 13 to 10 to recommend emergency authorization of Merck & Co Inc's (NYSE: MRK) molnupiravir, antiviral pill to treat COVID-19. Molnupiravir, developed with Ridgeback Biotherapeutics, targets part of the virus called the RNA polymerase that has not been changed much by mutations in the Omicron variant.

AdComm Narrowly Backs Merck's COVID-19 Pill, Despite Efficacy Questions

A pill that could reduce severe Covid symptoms has gained the narrow backing of US health regulators. Merck & Co Inc (NYSE:MRK)'s antiviral treatment molnupiravir was cleared for use by a panel of experts from the Food & Drug Administration, which voted 13 to 10 in favour of the new drug.

Merck's new Covid pill gets the US regulatory green light - but only just

The financial ratios that tend to lead price action show good things for MRK's stock price. Treating MRK as a value stock and considering its fundamentals and pipeline, we can expect upward momentum sometime in the near future.

Merck Is A Buy Now

Merck continues to impress with strong growth in its key franchises. It maintains a very strong balance sheet, and just increased its dividend, which remains well-covered by earnings.

Bargain Alert: Merck Is A Strong Buy On The Drop

The FDA still needs to officially authorize molnupiravir for people at high risk of severe COVID-19.

FDA panel narrowly moves to authorize Merck's COVID treatment pill

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Statement on Positive FDA Vote for Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults

Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults

A COVID-19 pill could prevent infected people from getting seriously sick. But the FDA panel expressed concerns over the safety of Merck's antiviral.

An FDA expert panel narrowly supports the first COVID-19 pill but suggests restrictions on its use driven by safety concerns

The FDA's Antimicrobial Drugs Advisory Committee voted 13 to 10 to recommend emergency authorization of molnupiravir.

FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions

Merck's pill is the first oral medication to be endorsed for authorization in the United States.

FDA Panel Recommends Merck's Covid-19 Antiviral Pill For Emergency Use Authorization

On Monday, Merck & Co Inc. (NYSE:MRK) shares plunged by more than 5% amid concerns about the efficacy of its molnupiravir drug as a treatment for covid-19. The pill is poised for authorisation by the US Food and Drug Administration (FDA), but analysts fear its efficacy could hamper use.

Is Merck stock a buy or sell as covid pill efficacy concerns send shares crushing?

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces First-Quarter 2022 Dividend

Merck Announces First-Quarter 2022 Dividend

Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.

Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas

A Food and Drug Administration advisory committee is meeting Tuesday to decide whether the benefits of Merck's experimental antiviral COVID-19 pill outweigh its risks.

FDA advisers to vote Tuesday on Merck's COVID-19 pill even as interest has waned

The stock price of Merck has seen an 8% fall in a month, while it was down nearly 4% on Friday, Nov 26. This can largely be attributed to the company's recently shared data for its Covid-19 antiviral pill - Molnupiravir - which shows lower efficacy of 30% against hospitalization and death in high.

Is A Rise Imminent For Merck Stock After An 8% Fall In A Month?

The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer. The application for Lynparza covers the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients Esophageal Carcinoma

Merck's KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma

Merck & Co. Inc. MRK, -5.39% and AstraZeneca PLC AZN, -1.86% said Tuesday that their supplemental New Drug Application (sNDA) for its breast cancer treatment Lynparza has been accepted and granted priority review by the U.S. Food and Drug Administration. Lynparza's sNDA is for the adjuvant treatment of patients with BRCA-mutated, human epidermal growth factor receptor 2-negative high-risk early breast cancer who have already been treated with chemotherapy.

Merck, AstraZeneca's sNDA for breast cancer treatment granted priority review by the FDA

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts Submission of sNDA for LYNPARZAas Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer; Grants Priority Review.

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review

Key advisers to the FDA are scheduled to meet Tuesday, November 30, to decide emergency use authorization to Merck & Co Inc's (NYSE: MRK) experimental pill to treat COVID-19. Members of the agency's Antimicrobial Drugs Advisory Committee will scrutinize the Company's data before voting on whether its overall benefits outweigh its risks.

News for Merck Stock (MRK)